Phase I/II Evaluation of Topical Betulinic Acid In the Treatment of Dysplastic Nevi with Moderate to Severe Dysplasia
This study is currently recruiting patients.
Sponsored by: University of Illinois at Chicago, Department of Surgical Oncology
Information provided by: University of Illinois at Chicago, Department of Surgical Oncology
The purpose of this study is to evaluate the safety and effectiveness of an experimental 20% betulinic acid ointment (BA ointment) as a treatment for dysplastic nevi with the potential to transform into melanoma.
Approximately 200 subjects may be enrolled and screened in order to find 28 subjects who qualify to be involved in this research at UIC.
Dysplastic melanocytic nevus (DMN) is a histopathologic term implying a disordered proliferation of melanocytes associated with discontinuous and variable cellular atypia. DMN is graded into mild, moderate, and severe based on standard histological criteria. DMN is considered to be a likely precursor for melanoma, and individuals with DMN often have multiple instances of it scattered over their trunk and extremities. For this study, only DMN where the dysplasia is either moderate or severe will be included.Inclusion Criteria
1.Age range: 18 years or older
2.Gender: Both male and female
3.Race: All races are eligible for entry into the Study
4.All patients must have been histologically documented (by a punch biopsy) for dysplastic nevi with moderate to severe dysplasia (DMN). A similar biopsy proven DMN that will serve as the control needs to be available.
5.Patients must be healthy and active in normal pursuits of life and be able to provide informed written consent.
6.Localized dermatological conditions like psoriasis or actinic keratosis will not be an exclusion criteria.
7.Patients must be ambulatory with an ECOG status < 2 (see Appendix 3); they will not be hospitalized as part of the Study.
8.All patients in this study will have, in addition to a normal clinical examination, a thorough skin examination. Whenever possible, periodic photographs of their lesions will be taken. Additional tests for all patients within 30 days of the initiation of topical application include urinalysis, a liver function test (LFT), and blood tests for complete blood count (CBC), BUN, and creatinine.
1.Women who are pregnant and/or nursing will be excluded. A pregnancy test will be performed on each pre-menopausal woman within two days of entry into the Study, and a negative pregnancy test must be recorded on the case report form prior to initiating use of the topical application.
2.Patients who are being treated for other chronic debilitating diseases (cardiac, pulmonary, or any other organ specific diseases).
3.Immuno-suppressed patients, either due to chemotherapy and radiation therapy or known immunodeficiency diseases (e.g., AIDS).
4.Patients with other active malignancies within the past five years, excluding noninvasive skin or cervical carcinoma.
5.Patients with any other serious medical or psychiatric illness that would prevent informed consent.
6.Patients with extensive chronic skin diseases such as extensive psoriasis, atopic dermatitis, or xeroderma pigmentosa will be excluded from the Study.
Location and Contact Information
Cathleen Schaeffer: 312-413-3863Illinois: University of Illinois Medical Center, Chicago, Illinois 60612, United States